Monitoring tolerance and rejection in organ transplant recipients

References

• Altermann W, Schlaf G, Rothhoff A, Seliger B. (2007). High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection? Nephrol Dial Transplant 22:2795–2799.
   PubMed Web of Science ®Google Scholar
• Andree H, Nickel P, Nasiadko C, Hammer MH, Schönemann C, Pruss A, Volk HD, Reinke P. (2006). Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 17:573–580.
   PubMed Web of Science ®Google Scholar
• Aubert V, Venetz JP, Pantaleo G, Pascual M. (2009). Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 70:580–583.
   PubMedGoogle Scholar
• Augustine JJ, Poggio ED, Clemente M, Aeder MI, Bodziak KA, Schulak JA, Heeger PS, Hricik DE. (2007). Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol 18:1602–1606.
   Google Scholar
• Baeten D, Louis S, Braud C, Braudeau C, Ballet C, Moizant F, Pallier A, Giral M, Brouard S, Soulillou JP. (2006). Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 17:294–304.
   PubMed Web of Science ®Google Scholar
• Bellisola G, Tridente G, Nacchia F, Fior F, Boschiero L. (2006). Monitoring of cellular immunity by interferon-γ enzyme-linked immunosorbent spot assay in kidney allograft recipients: preliminary results of a longitudinal study. Transplant Proc 38:1014–1017.
   Google Scholar
• Berglund D, Bengtsson M, Biglarnia A, Berglund E, Yamamoto S, von Zur-Mühlen B, Lorant T, Tufveson G. (2011). Screening of mortality in transplant patients using an assay for immune function. Transpl Immunol (In Press).
   Google Scholar
• Bloom D, Chang Z, Pauly K, Kwun J, Fechner J, Hayes C, Samaniego M, Knechtle S. (2009). BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 9:1835–1845.
   PubMed Web of Science ®Google Scholar
• Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC, Baeten D, Zhang M, Ashton-Chess J, Braudeau C, Hsieh F, Dupont A, Pallier A, Moreau A, Louis S, Ruiz C, Salvatierra O, Soulillou JP, Sarwal M. (2007). Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci usa 104:15448–15453.
   PubMed Web of Science ®Google Scholar
• Brown K, Moxham V, Karegli J, Phillips R, Sacks SH, Wong W. (2007). Ultra-localization of Foxp3+ T cells within renal allografts shows infiltration of tubules mimicking rejection. Am J Pathol 171:1915–1922.
   Google Scholar
• Codarri L, Vallotton L, Ciuffreda D, Venetz JP, Garcia M, Hadaya K, Buhler L, Rotman S, Pascual M, Pantaleo G. (2007). Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL-7Rα high cell population in solid organ transplant recipients. J Exp Med 204:1533–1541.
   Google Scholar
• Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA, Tary-Lehmann M. (1999). Pretransplant frequency of donor-specific, IFN-γ-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 163:2267–2275.
   PubMed Web of Science ®Google Scholar
• Heinemann FM, Rebmann V, Witzke O, Philipp T, Broelsch CE, Grosse-Wilde H. (2007). Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 83:706–711.
   PubMed Web of Science ®Google Scholar
• Ho J, Rush DN, Gibson IW, Karpinski M, Storsley L, Bestland J, Stefura W, HayGlass KT, Nickerson PW. (2010). Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 90:394–400.
   PubMed Web of Science ®Google Scholar
• Hooper E, Hawkins DM, Kowalski RJ, Post DR, Britz JA, Brooks KC, Turman MA. (2005). Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant 19:834–839.
   PubMed Web of Science ®Google Scholar
• Hu H, Kwun J, Aizenstein BD, Knechtle SJ. (2009). Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 87:1814–1820.
   PubMed Web of Science ®Google Scholar
• Huskey J, Gralla J, Wiseman AC. (2011). Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol 6:423–429.
   PubMed Web of Science ®Google Scholar
• Israeli M, Klein T, Sredni B, Avitzur Y, Mor E, Bar-Nathen N, Steinberg R, Dinari G, Shapiro R. (2008). ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl 14:893–898.
   Google Scholar
• Israeli M, Yussim A, Mor E, Sredni B, Klein T. (2007). Preceeding the rejection: in search for a comprehensive post-transplant immune monitoring platform. Transpl Immunol 18:7–12.
   PubMed Web of Science ®Google Scholar
• Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW Jr, Colvin RB, Sykes M, Sachs DH. (2008). HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 358:353–361.
   PubMed Web of Science ®Google Scholar
• Kers J, Xu-Dubois YC, Rondeau E, Claessen N, Idu MM, Roelofs JJ, Bemelman FJ, ten Berge IJ, Florquin S. (2010). Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy. Transplantation 90:502–509.
   Google Scholar
• Kim SH, Oh EJ, Kim MJ, Park YJ, Han K, Yang HJ, Kim JY, Choi BS, Yang CW, Kim YS, Bang BK. (2007). Pretransplant donor-specific interferon-γ ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant Proc 39:3057–3060.
   PubMed Web of Science ®Google Scholar
• Kotsch K, Mashreghi MF, Bold G, Tretow P, Beyer J, Matz M, Hoerstrup J, Pratschke J, Ding R, Suthanthiran M, Volk HD, Reinke P. (2004). Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 77:1866–1875.
   PubMed Web of Science ®Google Scholar
• Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, Burdick J, Elmagd KA, Zeevi A, Lopez-Cepero M, Daller JA, Gritsch HA, Reed EF, Jonsson J, Hawkins D, Britz JA. (2006). Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82:663–668.
   PubMed Web of Science ®Google Scholar
• Kowalski RJ, Zeevi A, Mannon RB, Britz JA, Carruth LM. (2007). Immunodiagnostics: evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers. J Immunotoxicol 4:225–232.
   Web of Science ®Google Scholar
• Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, Pratschke J, Rudolph B, Schmidt D, Salama A, Schönemann C. (2009). Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 87:1505–1513.
   PubMed Web of Science ®Google Scholar
• Langan LL, Park LP, Hughes TL, Irish A, Luxton G, Witt CS, Christiansen FT. (2007). Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 7:847–856.
   PubMed Web of Science ®Google Scholar
• Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B, Serur D, Mouradian J, Schwartz JE, Suthanthiran M. (2001). Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 344:947–954.
   PubMed Web of Science ®Google Scholar
• Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N, Moreau A, Soulillou JP, Brouard S. (2006). Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 81:398–407.
   PubMed Web of Science ®Google Scholar
• Mathew JM, Ciancio G, Burke GW, Garcia-Morales RO, Rosen A, Wang E, Gomez CI, Blomberg BB, Fuller L, Esquenazi V, Ricordi C, Miller J. (2010). Immune “tolerance profiles” in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol 71:566–576.
   Google Scholar
• Matz M, Beyer J, Wunsch D, Mashreghi MF, Seiler M, Pratschke J, Babel N, Volk HD, Reinke P, Kotsch K. (2006). Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 69:1683–1690.
   PubMed Web of Science ®Google Scholar
• Mengel M, Gwinner W, Schwarz A, Bajeski R, Franz I, Bröcker V, Becker T, Neipp M, Klempnauer J, Haller H, Kreipe H. (2007). Infiltrates in protocol biopsies from renal allografts. Am J Transplant 7:356–365.
   PubMed Web of Science ®Google Scholar
• Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M. (2005). Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353:2342–2351.
   PubMed Web of Science ®Google Scholar
• Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL; Immune Tolerance Network ST507 Study Group. (2010). Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120:1836–1847.
   PubMed Web of Science ®Google Scholar
• Nickel P, Presber F, Bold G, Biti D, Schönemann C, Tullius SG, Volk HD, Reinke P. (2004). Enzyme-linked immunosorbent spot assay for donor-reactive interferon-γ-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 78:1640–1646.
   PubMed Web of Science ®Google Scholar
• Opelz G; Collaborative Transplant Study. (2005). Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365:1570–1576.
   PubMed Web of Science ®Google Scholar
• Opelz G, Claas FH. (2009). Which human leukocyte antigen antibodies are really clinically relevant? Hum Immunol 70:561–562.
   Google Scholar
• Patel AM, Pancoska C, Mulgaonkar S, Weng FL. (2007). Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 7:2371–2377.
   Google Scholar
• Pelzl S, Opelz G, Wiesel M, Schnülle P, Schönemann C, Döhler B, Süsal C. (2002). Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73:3–6.
   Google Scholar
• Platt RE, Wu KS, Poole K, Newstead CG, Clark B. (2009). Soluble CD30 as a prognostic factor for outcome following renal transplantation. J Clin Pathol 62:662–663.
   Google Scholar
• Poggio ED, Augustine JJ, Clemente M, Danzig JM, Volokh N, Zand MS, Hricik DE, Heeger PS. (2007). Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 83:847–852.
   PubMed Web of Science ®Google Scholar
• Poggio ED, Clemente M, Hricik DE, Heeger PS. (2006). Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 17:564–572.
   PubMed Web of Science ®Google Scholar
• Porcheray F, Wong W, Saidman SL, De Vito J, Girouard TC, Chittenden M, Shaffer J, Tolkoff-Rubin N, Dey BR, Spitzer TR, Colvin RB, Cosimi AB, Kawai T, Sachs DH, Sykes M, Zorn E. (2009). B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant 9:2126–2135.
   PubMed Web of Science ®Google Scholar
• Quintana LF, Solé-Gonzalez A, Kalko SG, Bañon-Maneus E, Solé M, Diekmann F, Gutierrez-Dalmau A, Abian J, Campistol JM. (2009). Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 20:428–435.
   PubMed Web of Science ®Google Scholar
• Reinsmoen NL, Cornett KM, Kloehn R, Burnette AD, McHugh L, Flewellen BK, Matas A, Savik K. (2008). Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. Transplantation 85:462–470.
   Google Scholar
• Rodriguez DS, Jankowska-Gan E, Haynes LD, Leverson G, Munoz A, Heisey D, Sollinger HW, Burlingham WJ. (2004). Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transplant 4:537–543.
   Google Scholar
• Rodríguez LM, París SC, Arbeláez M, Cotes JM, Süsal C, Torres Y, García LF. (2007). Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 68:652–660.
   PubMed Web of Science ®Google Scholar
• Rossano JW, Denfield SW, Kim JJ, Price JF, Jefferies JL, Decker JA, Smith EO, Clunie SK, Towbin JA, Dreyer WJ. (2009). Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients. J Heart Lung Transplant 28:26–31.
   Google Scholar
• Rush D. (2009). Can protocol biopsy better inform our choices in renal transplantation? Transplant Proc 41:S6–S8.
   PubMedGoogle Scholar
• Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI. (2010). Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120:1848–1861.
   PubMed Web of Science ®Google Scholar
• Saini D, Ramachandran S, Nataraju A, Benshoff N, Liu W, Desai N, Chapman W, Mohanakumar T. (2008). Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 8:1798–1808.
   PubMed Web of Science ®Google Scholar
• Sánchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernández-Fresnedo G, López-Hoyos M, Piñera C, Palomar R, Leyva-Cobián F, Arias M. (2008). Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant 22:55–60.
   PubMed Web of Science ®Google Scholar
• Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O Jr. (2003). Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349:125–138.
   PubMed Web of Science ®Google Scholar
• Sawitzki B, Bushell A, Steger U, Jones N, Risch K, Siepert A, Lehmann M, Schmitt-Knosalla I, Vogt K, Gebuhr I, Wood K, Volk HD. (2007). Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 7:1091–1102.
   PubMed Web of Science ®Google Scholar
• Sawitzki B, Schlickeiser S, Reinke P, Volk HD. (2009). Pretransplant immune risk assessment. Curr Opin Organ Transplant 14:650–655.
   Google Scholar
• Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M, Stefura W, Hayglass K. (2009). Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 9:1347–1353.
   PubMed Web of Science ®Google Scholar
• Schlaf G, Altermann WW, Rothhoff A, Seliger B. (2007). Soluble CD30 serum level–an adequate marker for allograft rejection of solid organs? Histol Histopathol 22:1269–1279.
   PubMed Web of Science ®Google Scholar
• Seiler M, Brabcova I, Viklicky O, Hribova P, Rosenberger C, Pratschke J, Lodererova A, Matz M, Schönemann C, Reinke P, Volk HD, Kotsch K. (2007). Heightened expression of the cytotoxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation. Am J Transplant 7:423–433.
   PubMedGoogle Scholar
• Serban G, Whittaker V, Fan J, Liu Z, Manga K, Khan M, Kontogianni K, Padmanabhan A, Cohen D, Suciu-Foca N, Ratner L, Colovai AI. (2009). Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy. Hum Immunol 70:882–890.
   PubMed Web of Science ®Google Scholar
• Seveso M, Bosio E, Ancona E, Cozzi E. (2009). De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact. Contrib Nephrol 162:87–98.
   Google Scholar
• Slavcev A, Honsova E, Lodererova A, Pavlova Y, Sajdlova H, Vitko S, Skibova J, Striz I, Viklicky O. (2007). Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transpl Immunol 18:22–27.
   Google Scholar
• Sottong PR, Rosebrock JA, Britz JA, Kramer TR. (2000). Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 7:307–311.
   PubMedGoogle Scholar
• Spiridon C, Nikaein A, Lerman M, Hunt J, Dickerman R, Mack M. (2008). CD30, a marker to detect the high-risk kidney transplant recipients. Clin Transplant 22:765–769.
   PubMed Web of Science ®Google Scholar
• Süsal C, Pelzl S, Döhler B, Opelz G. (2002). Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13:1650–1656.
   PubMedGoogle Scholar
• Süsal C, Pelzl S, Opelz G. (2003). Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 76:1231–1232.
   Google Scholar
• Tatapudi RR, Muthukumar T, Dadhania D, Ding R, Li B, Sharma VK, Lozada-Pastorio E, Seetharamu N, Hartono C, Serur D, Seshan SV, Kapur S, Hancock WW, Suthanthiran M. (2004). Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 65:2390–2397.
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Kreisler M, Mickey RM. (1971). Presensitization and kidney transplant failures. Postgrad Med j 47:89–100.
   PubMed Web of Science ®Google Scholar
• Vasilescu ER, Ho EK, Colovai AI, Vlad G, Foca-Rodi A, Markowitz GS, D’Agati V, Hardy MA, Ratner LE, Suciu-Foca N. (2006). Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 67:597–604.
   Web of Science ®Google Scholar
• Veronese F, Rotman S, Smith RN, Pelle TD, Farrell ML, Kawai T, Benedict Cosimi A, Colvin RB. (2007). Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant 7:914–922.
   PubMed Web of Science ®Google Scholar
• Volk HD, Kern F. (2001). Insights into the specificity and function of (allo)antigen-reactive T cells. Am J Transplant 1:109–114.
   Google Scholar
• Xu H, He X, Liu Q, Shi D, Chen Y, Zhu Y, Zhang X. (2009a). Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. Transplant Proc 41:1552–1556.
   PubMed Web of Science ®Google Scholar
• Xu H, He X, Sun J, Shi D, Zhu Y, Zhang X. (2009b). The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant Proc 41:112–116.
   Google Scholar
• Yapici U, Bemelman FJ, Scheepstra CG, Roelofs JJ, Claessen N, van der Loos C, van Donselaar-van der Pant K, Bouts AH, Idu MM, Rowshani AT, ten Berge IJ, Florquin S. (2009). Intragraft FOXP3 protein or mRNA during acute renal allograft rejection correlates with inflammation, fibrosis, and poor renal outcome. Transplantation 87:1377–1380.
   Google Scholar
• Zarkhin V, Li L, Sarwal MM. (2009). BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 88:1229–1230.
   PubMed Web of Science ®Google Scholar